Arca
Skip to content
Tools
Tools

Glycogen storage disease type II

Drug research and approvals for glycogen storage disease type II: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 25 studies of glycogen storage disease type II are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 3 approved and 3 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 25
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 3
  • EU medicines: 4

Recruiting now

Newest posted first, of 25 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 1

Phase 2 2

Phase 1 or earlier 10

How its trials ended

148 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 33 whose ending is known, 42% met their primary endpoint, 3% missed it and 55% stopped early.

  • Completed, result not reported5235%
  • Ongoing4329%
  • Status unknown2014%
  • Met its primary endpoint149%
  • Stopped: other or unclear75%
  • Stopped: sponsor or business decision64%
  • Stopped: lack of efficacy21%
  • Stopped: funding21%
  • Missed its primary endpoint11%
  • Stopped: enrollment or feasibility11%

FDA orphan designations

Approved first, then open designations, newest first
Aug 1, 20141. Myozyme 2. Lumizyme(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)).Genzyme CorporationApproved
May 24, 20101. Myozyme 2. LumizymeLumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac…Genzyme CorporationApproved
Apr 28, 20061. Myozyme 2. LumizymeMyozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in…Genzyme CorporationApproved
Jan 9, 2017ClenbuterolTreatment of Pompe disease (glycogen storage disease type II)Avenue Therapeutics, Inc.Designated
Sep 20, 2000Recombinant human highly phosphorylated acid…For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)Novazyme Pharmaceuticals, Inc.Designated
Sep 10, 1996Human acid precursor alpha-glucosidase, recombinantTreatment of glycogen storage disease type II.Pharming/Genzyme LLCDesignated

Medicines authorised in the EU

Newest first
Jun 26, 2023OpfoldaMiglustatAmicus Therapeutics Europe LimitedEMA ↗
Mar 20, 2023PombilitiCipaglucosidase alfaAmicus Therapeutics Europe LimitedEMA ↗
Jun 24, 2022NexviadymeAvalglucosidase alfaSanofi B.V.EMA ↗
Mar 28, 2006MyozymeAlglucosidase alfaSanofi B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.